BISMUTH SUBCITRATE

Fatty Liver

Tehran University of Medical SciencesSmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

27 Active assets in the Fatty Liver cohort.

Asset / Sponsor	Phase	Rating
Metformin Leiden University Medical Center	Phase 4	BBB
Alpha Tocopherol Yuen Kah Hay	Phase 4	BB
Dolutegravir Fundacion SEIMC-GESIDA	Phase 4	BB
Empagliflozin Seoul National University Bundang Hospital	Phase 4	BB
Raltegravir Helsinki University Central Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

BISMUTH SUBCITRATE is also rated in:

Non-alcoholic Fatty Liver DiseaseDormant

B

Indicative ·

60 / 100

Liver DysfunctionDormant

B

Indicative ·

57 / 100

gastric mucosa-associated lymphoid tissue lymphomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.